CHRS (Coherus Oncology) EV-to-EBIT : -2.84 (As of Jul. 23, 2025)

Coherus Oncology EV-to-EBIT Chart

Coherus Oncology Annual Data
	Trend	Dec15	Dec16	Dec17	Dec18	Dec19	Dec20	Dec21	Dec22	Dec23	Dec24
EV-to-EBIT		Get a 7-Day Free Trial					7.24	-4.66	-3.52	-3.73	5.45

Coherus Oncology Quarterly Data
	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25
EV-to-EBIT	Get a 7-Day Free Trial															-2.51	-1.81	-1.99	5.45	-2.71

Competitive Comparison of Coherus Oncology's EV-to-EBIT

For the Biotechnology subindustry, Coherus Oncology's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Coherus Oncology's EV-to-EBIT Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Coherus Oncology's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Coherus Oncology's EV-to-EBIT falls into.

Coherus Oncology EV-to-EBIT Calculation

Coherus Oncology's EV-to-EBIT for today is calculated as:

Coherus Oncology's current Enterprise Value is $294.4 Mil.
Coherus Oncology's EBIT for the trailing twelve months (TTM) ended in Mar. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was $-103.6 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Coherus Oncology  (NAS:CHRS) EV-to-EBIT Explanation

This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %.

Coherus Oncology's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Mar. 2025 is calculated as:

Coherus Oncology's Enterprise Value for the quarter that ended in Mar. 2025 was $281.1 Mil.
Coherus Oncology's EBIT for the trailing twelve months (TTM) ended in Mar. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was $-103.6 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Coherus Oncology EV-to-EBIT Related Terms

Thank you for viewing the detailed overview of Coherus Oncology's EV-to-EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.

Coherus Oncology Business Description